Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| PKC delta and epsilon in drug targeting and therapeutics. | 2009 |
|
| The safety and efficacy of KAI-1678- an inhibitor of epsilon protein kinase C (εPKC)-versus lidocaine and placebo for the treatment of postherpetic neuralgia: a crossover study design. | 2013 Apr |
|
| A single-center, randomized, double-blind, active, and placebo-controlled study of KAI-1678, a novel PKC-epsilon inhibitor, in the treatment of acute postoperative orthopedic pain. | 2013 Jun |
| Substance Class |
Protein
Created
by
admin
on
Edited
Sat Dec 16 10:10:58 GMT 2023
by
admin
on
Sat Dec 16 10:10:58 GMT 2023
|
| Protein Sub Type | |
| Sequence Type | COMPLETE |
| Record UNII |
32P8I5VL5A
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
124037376
Created by
admin on Sat Dec 16 10:10:58 GMT 2023 , Edited by admin on Sat Dec 16 10:10:58 GMT 2023
|
PRIMARY | |||
|
1253964-58-7
Created by
admin on Sat Dec 16 10:10:58 GMT 2023 , Edited by admin on Sat Dec 16 10:10:58 GMT 2023
|
NO STRUCTURE GIVEN | |||
|
KAI-1678
Created by
admin on Sat Dec 16 10:10:58 GMT 2023 , Edited by admin on Sat Dec 16 10:10:58 GMT 2023
|
PRIMARY | Official Title: A Double-Blind, Randomized, Placebo- and Active-Comparator-Controlled, Single-Dose Study to Assess the Efficacy of KAI-1678 Administered by Subcutaneous Infusion in Subjects With Postherpetic Neuralgia, Purpose: The purpose of this study is to determine whether KAI-1678 is effective in the treatment of postherpetic neuralgia pain, Primary Outcome Measures: The effect of KAI-1678 on mean change from baseline in pain intensity at 6 hours (PID 6). (Time Frame: Day 1) (Designated as safety issue: No) Measurements are made using a qualified pain scale and the change from basline is calculated at 6 hours. | ||
|
1041004-14-1
Created by
admin on Sat Dec 16 10:10:58 GMT 2023 , Edited by admin on Sat Dec 16 10:10:58 GMT 2023
|
PRIMARY | |||
|
32P8I5VL5A
Created by
admin on Sat Dec 16 10:10:58 GMT 2023 , Edited by admin on Sat Dec 16 10:10:58 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Originator: KAI Pharmaceuticals; Developer: Amgen; Class: Anti-inflammatory,Non-opioid analgesic, Peptide, Small molecule; Mechanism of Action: Protein kinase C epsilon inhibitor; Highest Development Phase: Discontinued for Neuropathic pain, Postoperative pain; Most Recent Events: 05 Jul 2012 KAI Pharmaceuticals has been acquired by Amgen, 22 Apr 2010 KAI Pharmaceuticals completes a phase IIa trial (NCT01106716) in Neuropathic pain in Australia, 21 Oct 2009 Pharmacodynamics data from a preclinical study in Neuropathic pain presented at the 39th Annual Meeting of the Society for Neuroscience (SfN-2009)
|
||
|
ACTIVE MOIETY |
KAI-1678, First-in-Class Compound, Enters Phase 2a Clinical Testing for the Treatment of Pain: KAI-1678 is an isozyme-selective, small peptide inhibitor of the epsilon protein kinase C pathway. Epsilon PKC is a well-validated target for both inflammatory and neuropathic pain in the preclinical, peer-reviewed scientific literature. KAIs approach is the first to enable the specificity of action required to make epsilon PKC inhibition a viable clinical approach.
KAI-1678 has been shown to be highly effective at reversing pain in preclinical models of both neuropathic and inflammatory pain.
|
||
|
ACTIVE MOIETY |
Synonym: KAI-1678, CAS Registry Number: 1253964-58-7, System Generated Number: 1253964587
|
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| MOL_WEIGHT:NUMBER AVERAGE(CALCULATED) | CHEMICAL |
|
||||
| Molecular Formula | CHEMICAL |
|